(Q41756673)

8 October 2017

1 reference

title

Clinical use of hematopoietic growth factors in the myelodysplastic syndromes (English)

1 reference

8 October 2017

Ganser A

1 reference

8 October 2017

Karthaus M

series ordinal

1 reference

8 October 2017

publication date

1 December 1997

1 reference

8 October 2017

1 reference

8 October 2017

volume

26 Suppl 1

1 reference

8 October 2017

page(s)

13-27

1 reference

Proposals for the classification of the myelodysplastic syndromes

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Serum erythropoietin concentrations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Establishing the incidence of myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Two types of acquired idiopathic sideroblastic anaemia (AISA)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Phase I study of recombinant human interleukin-3 in patients with bone marrow failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Induction of TNF-α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all- trans -retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

A common progenitor for human myeloid and lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199709058596

10.3109/10428199709058596

21 January 2018

Identifiers

DOI

1 reference

8 October 2017

1 reference